Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders

Biological Psychiatry

Volumn 70, Issue 1, 2011, Pages 7-12

  Carter, Cameron S ^a   Barch, Deanna M ^b   Bullmore, Edward ^c   Breiling, James ^d   Buchanan, Robert W ^e   Butler, Pamela ^f   Cohen, Jonathan D ^g   Geyer, Mark ^h   Gollub, Randy ⁱ   Green, Michael F ^j,k   Jaeger, Judith ^l   Krystal, John H ^m   Moore, Holly ⁿ   Nuechterlein, Keith ^o   Robbins, Trevor ^c   Silverstein, Steven ^p   Smith, Edward E ⁿ   Strauss, Milton ^q   Wykes, Til ^r  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f University of New York   (United States)

^g PRINCETON UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^l ASTRAZENECA   (United Kingdom)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ Och Spine at New York Presbyterian Hospitals   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^q UNIVERSITY OF NEW MEXICO   (United States)

^r KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

Biomarker; CNTRICS; cognition; schizophrenia; treatment

Indexed keywords

CLINICAL RESEARCH; COGNITION; COGNITIVE NEUROSCIENCE TREATMENT RESEARCH TO IMPROVE COGNITION IN SCHIZOPHRENIA; DRUG EFFECT; ELECTROENCEPHALOGRAPHY; EXPERIMENTAL ANIMAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAGNETOENCEPHALOGRAPHY; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); NEUROIMAGING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RELIABILITY; REVIEW; SCHIZOPHRENIA; THERAPY EFFECT; TRANSCRANIAL MAGNETIC STIMULATION; VALIDITY;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; BRAIN MAPPING; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; SCHIZOPHRENIA;

EID: 79958803157     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2011.01.041     Document Type: Review

References (10)

1. D.M. Barch, C.S. Carter, A. Arnsten, R.W. Buchanan, J.D. Cohen, and M. Geyer Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: Proceedings of the third CNTRICS meeting Schizophr Bull 35 2009 109 114
2. M. Minzenberg, and C.S. Carter The quest for developing new treatments from imaging techniques: Promises, problems and future potential Expert Opin Drugs Discov 2 2007 1029 1033 (Pubitemid 47354328)
3. P.M. Matthews, G.D. Honey, and E.T. Bullmore Applications of fMRI in translational medicine and clinical practice Nat Rev Neurosci 7 2006 732 744 (Pubitemid 44267497)
4. T.R. Insel, and B.N. Cuthbert Endophenotypes: Bridging genomic complexity and disorder heterogeneity Biol Psychiatry 66 2009 988 989
5. G. Aston-Jones, and J.I. Gold How we say no: Norepinephrine, inferior frontal gyrus, and response inhibition Biol Psychiatry 65 2009 548 549
6. M.J. Minzenberg, A.J. Watrous, J.H. Yoon, S. Ursu, and C.S. Carter Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI Science 322 2008 1700 1702
7. Luck SJ, Mathalon DH, O'Donnell BF, Hmlinen MS, Spencer KM, Javitt DC, Uhlhaas PJ (2011): A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research. Biol Psychiatry 70:xxxxxx.
8. McClintock SM, Freitas C, Oberman L, Lisanby SH, Pascual-Leone A (2011): Transcranial magnetic stimulation: A neuroscientific probe of cortical function in schizophrenia. Biol Psychiatry 70:xxxxxx.
9. Barch DM, Mathalon DH (2011): Using brain imaging measures in studies of procognitive pharmacologic agents in schizophrenia: Psychometric and quality assurance considerations. Biol Psychiatry 70:xxxxxx.
10. D.M. Barch, and C.S. Carter Measurement issues in the use of cognitive neuroscience tasks in drug development for impaired cognition in schizophrenia: A report of the second consensus building conference of the CNTRICS initiative Schizophr Bull 34 2008 613 618 (Pubitemid 351957561)